Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer

Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer - Recover HER2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014189

Enrollment

Registered

2014-06-06

Start date

2014-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive metastatic breast cancer

Interventions

lapatinib trastuzumab chemothrapies

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)histologically breast cancer 2) >20 y 3) PS 0-2 4)metastatic or advanced breast cancer 5)HER2 positve

Exclusion criteria

Exclusion criteria: 1) active synchuronous cancer 2) active infectious disease

Design outcomes

Primary

Measure	Time frame
CBR	—

Countries

Japan

Contacts

Public ContactMichiko Yago

JFCR Breast Med Oncol

michiko.yago@jfcr.or.jp03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026